Evgeny Kiselev1, Keli Agama, Yves Pommier, Mark Cushman. 1. Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, and The Purdue Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States.
Abstract
A comprehensive study of a series of azaindenoisoquinoline topoisomerase I (Top1) inhibitors is reported. The synthetic pathways have been developed to prepare 7-, 8-, 9-, and 10-azaindenoisoquinolines. The present study shows that 7-azaindenoisoquinolines possess the greatest Top1 inhibitory activity and cytotoxicity. Additionally, the introduction of a methoxy group into the D-ring of 7-azaindenoisoquinolines improved their biological activities, leading to new lead molecules for further development. A series of QM calculations were performed on the model "sandwich" complexes of azaindenoisoquinolines with flanking DNA base pairs from the Drug-Top1-DNA ternary complex. The results of these calculations demonstrate how changes in two forces contributing to the π-π stacking (dispersion and charge-transfer interactions) affect the binding of the drug to the Top1-DNA cleavage complex and thus modulate the drug's Top1 inhibitory activity.
A comprehensive study of a series of azaindenoisoquinoline topoisomerase I (Top1) inhibitors is reported. The synthetic pathways have been developed to prepare n class="Chemical">7-, 8-, 9-, and 10-azaindenoisoquinolines. The present study shows that 7-azaindenoisoquinolines possess the greatest Top1 inhibitory activity and cytotoxicity. Additionally, the introduction of a methoxy group into the D-ring of 7-azaindenoisoquinolines improved their biological activities, leading to new lead molecules for further development. A series of QM calculations were performed on the model "sandwich" complexes of azaindenoisoquinolines with flanking DNA base pairs from the Drug-Top1-DNA ternary complex. The results of these calculations demonstrate how changes in two forces contributing to the π-π stacking (dispersion and charge-transfer interactions) affect the binding of the drug to the Top1-DNA cleavage complex and thus modulate the drug's Top1 inhibitory activity.
Authors: Bart L Staker; Michael D Feese; Mark Cushman; Yves Pommier; David Zembower; Lance Stewart; Alex B Burgin Journal: J Med Chem Date: 2005-04-07 Impact factor: 7.446
Authors: P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd Journal: J Natl Cancer Inst Date: 1990-07-04 Impact factor: 13.506
Authors: Scott H Watterson; Ping Chen; Yufen Zhao; Henry H Gu; T G Murali Dhar; Zili Xiao; Shelley K Ballentine; Zhongqi Shen; Catherine A Fleener; Katherine A Rouleau; Mary Obermeier; Zheng Yang; Kim W McIntyre; David J Shuster; Mark Witmer; Donna Dambach; Sam Chao; Arvind Mathur; Bang-Chi Chen; Joel C Barrish; Jeffrey A Robl; Robert Townsend; Edwin J Iwanowicz Journal: J Med Chem Date: 2007-06-22 Impact factor: 7.446
Authors: Andrew Morrell; Michael Placzek; Seth Parmley; Smitha Antony; Thomas S Dexheimer; Yves Pommier; Mark Cushman Journal: J Med Chem Date: 2007-08-15 Impact factor: 7.446
Authors: Daniel E Beck; Monica Abdelmalak; Wei Lv; P V Narasimha Reddy; Gabrielle S Tender; Elizaveta O'Neill; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman Journal: J Med Chem Date: 2015-04-24 Impact factor: 7.446
Authors: Mohamed S A Elsayed; Yafan Su; Ping Wang; Taresh Sethi; Keli Agama; Azhar Ravji; Christophe E Redon; Evgeny Kiselev; Katharine A Horzmann; Jennifer L Freeman; Yves Pommier; Mark Cushman Journal: J Med Chem Date: 2017-06-28 Impact factor: 7.446
Authors: Peng-Cheng Lv; Mohamed S A Elsayed; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman Journal: J Med Chem Date: 2016-04-20 Impact factor: 7.446
Authors: Daniel E Beck; P V Narasimha Reddy; Wei Lv; Monica Abdelmalak; Gabrielle S Tender; Sophia Lopez; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman Journal: J Med Chem Date: 2016-04-12 Impact factor: 7.446